Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.58
(-0.83%)
CNY 3.58
(-0.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -121.22 Million CNY | -15418.37% |
| 2022 | 791.36 Thousand CNY | -99.38% |
| 2021 | 126.72 Million CNY | -65.78% |
| 2020 | 370.29 Million CNY | 162.56% |
| 2019 | 141.03 Million CNY | 14.82% |
| 2018 | 122.83 Million CNY | -45.51% |
| 2017 | 225.41 Million CNY | 46.01% |
| 2016 | 154.38 Million CNY | -8.01% |
| 2015 | 167.82 Million CNY | 27.84% |
| 2014 | 131.28 Million CNY | 48.18% |
| 2013 | 88.59 Million CNY | 27.98% |
| 2012 | 69.22 Million CNY | 37.5% |
| 2011 | 50.34 Million CNY | -11.89% |
| 2010 | 57.14 Million CNY | 22.25% |
| 2009 | 46.74 Million CNY | 62.54% |
| 2008 | 28.75 Million CNY | 23.0% |
| 2007 | 23.38 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -2.45 Million CNY | 73.83% |
| 2024 Q2 | -9.39 Million CNY | -250.27% |
| 2024 Q1 | 6.25 Million CNY | 104.73% |
| 2023 Q2 | -6.54 Million CNY | -184.11% |
| 2023 Q3 | 9.74 Million CNY | 248.84% |
| 2023 Q4 | -132.2 Million CNY | -1457.22% |
| 2023 FY | -121.22 Million CNY | -15418.37% |
| 2023 Q1 | 7.78 Million CNY | 102.28% |
| 2022 Q3 | 813.18 Thousand CNY | 102.73% |
| 2022 Q2 | -29.81 Million CNY | -493.43% |
| 2022 Q1 | 7.57 Million CNY | 122.26% |
| 2022 Q4 | -340.78 Million CNY | -42008.0% |
| 2022 FY | 791.36 Thousand CNY | -99.38% |
| 2021 Q3 | 7.22 Million CNY | -79.72% |
| 2021 Q4 | -34.03 Million CNY | -571.35% |
| 2021 Q2 | 35.6 Million CNY | -55.57% |
| 2021 Q1 | 80.13 Million CNY | -15.89% |
| 2021 FY | 126.72 Million CNY | -65.78% |
| 2020 Q4 | 95.27 Million CNY | -2.75% |
| 2020 FY | 370.29 Million CNY | 162.56% |
| 2020 Q1 | 59.96 Million CNY | 473.31% |
| 2020 Q2 | 117.08 Million CNY | 95.25% |
| 2020 Q3 | 97.97 Million CNY | -16.32% |
| 2019 Q3 | 7.55 Million CNY | -80.82% |
| 2019 Q4 | -16.06 Million CNY | -312.71% |
| 2019 FY | 141.03 Million CNY | 14.82% |
| 2019 Q1 | 41.36 Million CNY | 311.03% |
| 2019 Q2 | 39.37 Million CNY | -4.82% |
| 2018 Q3 | 5.78 Million CNY | -90.79% |
| 2018 Q1 | 73.79 Million CNY | 127.88% |
| 2018 FY | 122.83 Million CNY | -45.51% |
| 2018 Q4 | -19.6 Million CNY | -438.69% |
| 2018 Q2 | 62.85 Million CNY | -14.83% |
| 2017 Q4 | 32.38 Million CNY | -55.81% |
| 2017 Q2 | 56.95 Million CNY | -9.27% |
| 2017 Q3 | 73.29 Million CNY | 28.67% |
| 2017 FY | 225.41 Million CNY | 46.01% |
| 2017 Q1 | 62.77 Million CNY | 606.77% |
| 2016 Q1 | 56.69 Million CNY | 78.79% |
| 2016 Q3 | 63.38 Million CNY | 35.74% |
| 2016 Q4 | -12.38 Million CNY | -119.54% |
| 2016 FY | 154.38 Million CNY | -8.01% |
| 2016 Q2 | 46.69 Million CNY | -17.64% |
| 2015 Q4 | 31.71 Million CNY | -34.82% |
| 2015 Q2 | 43.51 Million CNY | -1.0% |
| 2015 Q1 | 43.95 Million CNY | 66.89% |
| 2015 FY | 167.82 Million CNY | 27.84% |
| 2015 Q3 | 48.64 Million CNY | 11.8% |
| 2014 FY | 131.28 Million CNY | 48.18% |
| 2014 Q2 | 34.03 Million CNY | 15.73% |
| 2014 Q4 | 26.33 Million CNY | -36.52% |
| 2014 Q3 | 41.49 Million CNY | 21.89% |
| 2014 Q1 | 29.41 Million CNY | 75.32% |
| 2013 Q2 | 19.18 Million CNY | -16.9% |
| 2013 FY | 88.59 Million CNY | 27.98% |
| 2013 Q3 | 29.54 Million CNY | 54.01% |
| 2013 Q4 | 16.77 Million CNY | -43.22% |
| 2013 Q1 | 23.08 Million CNY | 147.3% |
| 2012 Q4 | 9.33 Million CNY | -57.46% |
| 2012 Q1 | 17.83 Million CNY | 888.26% |
| 2012 Q2 | 20.11 Million CNY | 12.8% |
| 2012 Q3 | 21.94 Million CNY | 9.11% |
| 2012 FY | 69.22 Million CNY | 37.5% |
| 2011 Q4 | 1.8 Million CNY | -85.78% |
| 2011 Q2 | 20.34 Million CNY | 31.17% |
| 2011 Q1 | 15.5 Million CNY | 10.89% |
| 2011 FY | 50.34 Million CNY | -11.89% |
| 2011 Q3 | 12.69 Million CNY | -37.61% |
| 2010 Q3 | 16.1 Million CNY | -19.59% |
| 2010 Q1 | 7.01 Million CNY | 0.0% |
| 2010 Q2 | 20.03 Million CNY | 185.5% |
| 2010 Q4 | 13.98 Million CNY | -13.18% |
| 2010 FY | 57.14 Million CNY | 22.25% |
| 2009 FY | 46.74 Million CNY | 62.54% |
| 2008 FY | 28.75 Million CNY | 23.0% |
| 2007 FY | 23.38 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 2.34 Billion CNY | 105.165% |
| Realcan Pharmaceutical Group Co., Ltd. | -126.63 Million CNY | 4.274% |